A. Fritsche et al., Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion, DIABETOLOG, 43(7), 2000, pp. 852-858
Aims/hypothesis. Our studies were undertaken to characterise the defective
insulin secretion of impaired glucose tolerance (IGT).
Methods. We studied 13 normal glucose tolerant subjects (NGT) and 12 subjec
ts with IGT carefully matched for age, sex, BMI and waist-to-hip ratio. A m
odified hyperglycaemic clamp (10 mmol/l) with a standard 2-h square-wave hy
perglycaemia, an additional glucagon-like-peptide (GLP)-1 phase (1.5 pmol k
g(-1) min(-1) over 80 min) and a final arginine bolus (5 g) was used to ass
ess various phases of insulin secretion rate.
Results. Insulin sensitivity during the second phase of the hyperglycaemic
clamp was low in both groups but not significantly different (0.12 +/- 0.02
1 in NGT vs 0.11 +/- 0.013 mu mol kg(-1) min(-1) pmol(-1) in IGT, p = 0.61)
. First-phase insulin secretion was lower in IGT (1467 +/- 252 vs 3198 +/-
527 pmol min(-1), p = 0.008) whereas the second phase was not (677 +/- 61 v
s 878 +/- 117 pmol min(-1), p = 0.15). The acute insulin secretory peak in
response to GLP-1 was absent in IGT subjects who only produced a late phase
of GLP-1-induced insulin secretion rate which was lower (2228 +/- 188 pmol
min(-1)) than in NGT subjects (3056 +/- 327 pmol min(-1), p = 0.043). Insu
lin secretion in response to arginine was considerably although not signifi
cantly lower in IGT subjects. The relative impairment (per cent of the mean
rate for NGT subjects) was greatest for the GLP-1 peak (19 +/- 9 %).
Conclusion/interpretation. In this Caucasian cohort a defective insulin sec
retion rate is essential for the development of IGT. The variable degrees o
f impairment of different phases of the insulin secretion rate indicate tha
t several defects contribute to its abnormality in IGT. Defects in the incr
etin signalling pathway of the beta cell could contribute to the pathogenes
is of beta-cell dysfunction of IGT and thus Type II (non-insulin-dependent)
diabetes mellitus.